13-顺式维甲酸对骨髓增生异常综合征患者生存率的影响。
Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
作者信息
Clark R E, Jacobs A, Lush C J, Smith S A
出版信息
Lancet. 1987 Apr 4;1(8536):763-5. doi: 10.1016/s0140-6736(87)92796-6.
PMID:2882180
Abstract
A randomised therapeutic trial of 13-cis-retinoic acid was carried out in 70 patients with myelodysplastic syndrome having 5% or fewer marrow blast cells. Among non-sideroblastic patients the 1-year survival in the treated group was 77%, compared with 36% in the control group. There were too few deaths among patients with sideroblastic anaemia to allow any effect of therapy on survival to be evaluated.
摘要
对70例骨髓母细胞占骨髓5%或更少的骨髓增生异常综合征患者进行了13-顺式维甲酸的随机治疗试验。在非铁粒幼细胞性患者中，治疗组的1年生存率为77%，而对照组为36%。铁粒幼细胞性贫血患者的死亡人数太少，无法评估治疗对生存的任何影响。
Zotero 插件